智通财经APP讯，迪哲医药(688192.SH)发布2026年半年度业绩预告，公司预计2026年半年度归属于母公司所有者的净亏损2.1亿元左右，同比亏损减少44.35%左右。预计2026年半年度归属于母公司所有者的扣除非经常性损益后的净亏损2.31亿元左右，同比亏损减少44.90%左右。
报告期内，公司已获批的两款产品舒沃哲®(通用名：舒沃替尼片)和高瑞哲®(通用名：戈利昔替尼胶囊)，在国家医保政策的支持与覆盖下，凭借突出的差异化临床优势，患者的可及性持续提升，产品市场份额持续扩大，推动公司经营业绩持续向好，预计2026年半年度实现营业收入5.22亿元左右。公司2026年半年度营业收入大幅增长，同时产品研发进展较为顺利，研发投入仍保持较高水平，预计2026年半年度将继续出现归属于母公司所有者的净利润为负的情况，但公司主营业务、核心竞争力没有发生重大不利变化。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.